Immatics N.V [IMTX] vs Recursion [RXRX] Detailed Stock Comparison

Immatics N.V.

NASDAQ
Loading...

Recursion Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Immatics N.V. wins in 10 metrics, Recursion Pharmaceuticals Inc. wins in 8 metrics, with 0 ties. Immatics N.V. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Immatics N.V. Recursion Pharmaceuticals Inc. Better
P/E Ratio (TTM) 26.82 -2.44 Immatics N.V.
Price-to-Book Ratio 2.62 1.64 Recursion Pharmaceuticals Inc.
Debt-to-Equity Ratio 3.23 6.89 Immatics N.V.
PEG Ratio -6.31 0.04 Recursion Pharmaceuticals Inc.
EV/EBITDA -6.05 -2.10 Recursion Pharmaceuticals Inc.
Profit Margin (TTM) 0.00% 4.45% Recursion Pharmaceuticals Inc.
Operating Margin (TTM) -196.76% -328.80% Immatics N.V.
Return on Equity -37.10% -59.54% Immatics N.V.
Return on Assets (TTM) -18.08% -27.72% Immatics N.V.
Free Cash Flow (TTM) $-183.43M $-380.44M Immatics N.V.
1-Year Return 113.54% -14.11% Immatics N.V.
Price-to-Sales Ratio (TTM) 31.06 24.83 Recursion Pharmaceuticals Inc.
Enterprise Value $1.23B $1.19B Immatics N.V.
EV/Revenue Ratio 21.66 15.88 Recursion Pharmaceuticals Inc.
Gross Profit Margin (TTM) N/A 59.62% N/A
Revenue per Share (TTM) $0 $0 Immatics N.V.
Earnings per Share (Diluted) $-1.89 $-1.44 Recursion Pharmaceuticals Inc.
Beta (Stock Volatility) 1.34 1.01 Recursion Pharmaceuticals Inc.
Short % of Float 5.63% 34.94% Immatics N.V.

Immatics N.V. vs Recursion Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

IMTX
RXRX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Immatics N.V.1.64%-10.45%-8.44%3.66%-1.35%-2.39%
Recursion Pharmaceuticals Inc.-3.88%9.46%-1.42%-1.98%-25.54%-17.38%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Immatics N.V.113.54%13.06%-4.16%19.90%19.90%19.90%
Recursion Pharmaceuticals Inc.-14.11%-56.38%-87.80%-88.53%-88.53%-88.53%

Performance & Financial Health Analysis: Immatics N.V. vs Recursion Pharmaceuticals Inc.

MetricIMTXRXRX
Market Information
Market Cap i$1.50B$1.85B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i293,18611,402,630
90 Day Avg. Volume i516,55512,390,473
Last Close$10.20$3.47
52 Week Range$5.05 - $12.41$2.77 - $7.18
% from 52W High-17.77%-51.67%
All-Time High$18.42 (Mar 15, 2021)$42.81 (Jul 12, 2021)
% from All-Time High-44.63%-91.89%
Growth Metrics
Quarterly Revenue Growth-0.65%6.82%
Quarterly Earnings Growth-0.65%6.84%
Financial Health
Profit Margin (TTM) i0.00%0.04%
Operating Margin (TTM) i-1.97%-3.29%
Return on Equity (TTM) i-0.37%-0.60%
Debt to Equity (MRQ) i3.236.89
Cash & Liquidity
Book Value per Share (MRQ)$4.26$2.14
Cash per Share (MRQ)$3.50$1.41
Operating Cash Flow (TTM) i$-208,159,039$-371,808,000
Levered Free Cash Flow (TTM) i$-151,076,052$-208,521,744
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Immatics N.V. vs Recursion Pharmaceuticals Inc.

MetricIMTX (Apr 24, 2026)RXRX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i26.82-2.44
Forward P/E i-6.31-4.12
PEG Ratio i-6.310.04
Price to Sales (TTM) i31.0624.83
Price to Book (MRQ) i2.621.64
Market Capitalization
Market Capitalization i$1.50B$1.85B
Enterprise Value i$1.23B$1.19B
Enterprise Value Metrics
Enterprise to Revenue i21.6615.88
Enterprise to EBITDA i-6.05-2.10
Risk & Other Metrics
Beta i1.341.01
Book Value per Share (MRQ) i$4.26$2.14

Financial Statements Comparison: Immatics N.V. vs Recursion Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricIMTX (2025)RXRX (2025)
Revenue/Sales i48.27M74.26M
Cost of Goods Sold iN/A70.95M
COGS % of Revenue i0.0%95.6%
Gross Profit iN/A3.30M
Gross Margin i0.0%4.4%
Research & Development i183.83M475.27M
Operating Income (EBIT) i-182.02M-648.13M
Operating Margin i-377.1%-872.8%
EBITDA i-152.44M-559.38M
EBITDA Margin i-315.8%-753.3%
Pre-Tax Income i-198.44M-644.90M
Pre-Tax Income % of Revenue i-411.1%-868.5%
Income Tax i-1.99M-136,000
Income Tax % of Revenue i-4.1%-0.2%
Net Income (Profit) i-196.45M-644.76M
Profit Margin i-407.0%-868.3%

Balance Sheet & Liquidity Metrics

MetricIMTX (2025)RXRX (2025)
Cash & Equivalents i345.92M743.29M
Total Current Assets i504.01M812.85M
Total Current Assets % of Revenue i1,044.2%1,094.7%
Total Current Liabilities i43.01M147.71M
Total Current Liabilities % of Revenue i89.1%198.9%
Long-Term Debt i12.88M56.21M
Long-Term Debt % of Revenue i26.7%75.7%
Total Shareholders Equity i484.10M1.13B
Retained Earnings i-785.99M-2.08B
Retained Earnings % of Revenue i-1,628.5%-2,795.7%
Property, Plant & Equipment i34.41M158.71M

Cash Flow Statement Comparison

MetricIMTX (2025)RXRX (2025)
Operating Cash Flow i-231.22M-422.39M
Operating Cash Flow % of Revenue i-479.1%-568.8%
Capital Expenditures i-6.56M-6.47M
Free Cash Flow i-183.43M-380.44M
FCF Margin i-380.0%-512.3%
Debt Repayment i-2.96M-8.43M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricIMTXRXRX
Shares Short i5.17M174.40M
Short Ratio i8.5414.00
Short % of Float i5.63%34.94%
Shares Outstanding i134.07M528.18M
Float Shares i69.33M510.29M
% Held by Insiders i17.92%2.85%
% Held by Institutions i76.44%64.60%
% Held by Public i5.64%32.55%

Dividend Analysis & Yield Comparison: Immatics N.V. vs Recursion Pharmaceuticals Inc.

MetricIMTXRXRX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A